Abstract
BackgroundAlthough the mitogen-activated protein kinases (MAPK) pathway is hyperactive in head and neck cancer (HNC), inhibition of MEK1/2 in HNC patients has not shown clinically meaningful activity. Therefore, we aimed...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have